Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label givinostat extension in previously treated Duchenne muscular dystrophy patients
2023-504520-26-00Phase 3Authorised
- Sponsor
- Italfarmaco
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Planned start Oct 2017; status: authorised.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2023-504520-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504520-26-00.